Suitability of a minipig model in assessing clinical bioperformance of matrix and multiparticulate extended-release formulations for a BCS class III Drug development candidate.

Preclinical studies in dogs are often employed as part of formulation screening process. However, the shorter transit time and colonic length in dogs may result in underestimation of absorption, especially for extended-release (ER) formulations. In the recent years, minipigs have attracted attention as an alternative animal model.